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The introduction of the techniques of molecular biol­
ogy as tools to study skin carcinogenesis has provided 
more precise localization of biochemical pathways 
that regulate the tumor phenotype. This approach has 
identified genetic changes that are characteristic of 
each of the specific stages of squamous cancer patho­
genesis: initiation, exogenous promotion, premalig­
nant progression, and malignant conversion. Initiation 
can result from mutations in a single gene, and the 
Harvey allele of the ras gene family has been identified 
as a frequent site for initiating mutations. Heterozy­
gous activating mutations in c-rasH- are dominant, and 
affected keratinocytes hyperproliferate and are resist­
ant to signals for terminal differentiation. An impor­
tant pathway impacted by c-rasH- activation is the pro­
tein kinase C (PKC) pathway, a major regulator of 
keratinocyte differentiation. Increased activity of 
PKCa and suppression ofPKC6by tyrosine phospho­
rylation contribute to the phenotypic consequences of 
rasH- gene activation in keratinocytes. Tumor promot­
ers disturb epidermal homeostasis and cause selective 
clonal expansion of initiated cells to produce multiple 
benign squamous papillomas. Resistance to differen-
T he introduction of the techniques of molecular biol­ogy as tools to study skin carcinogenesis has provided more precise localization of pathways that regulate the tumor phenotype. However, the application of these tools to answer relevant questions has depended 
on the establishment of a conceptual framework that developed 
over four decades of research on the biology and cellular physiology 
of skin cancer induction by chemical exposures. These studies indi­
cated that predictable and progressive stages occurred during the 
clonal evolution of a normal keratinocyte into a squamous cell car­
cinoma, and both genetic and epigenetic events contributed to these 
changes [1]. Progress in understanding carcinogenesis was enhanced 
when certain properties associated with a particular stage of skin 
cancer pathogenesis were characterized [1]. Operational analyses, 
which defined the experimental requirements to produce a specific 
neoplastic phenotype, have also been important for understanding 
the process of tumor development (Fig 1). 
The earliest event documented in skin carcinogenesis, initiation, 
is carcinogen induced and mutational in nature. Initiated keratino­
cytes express a subtle change in phenotype, unrecognizable in the 
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tiation and enhanced growth rate of initiated cells im­
part a growth advantage when the epidermis is exposed 
to promoters. The frequency of premalignant progres­
sion varies among papillomas, and subpopulations at 
high risk for progression have been identified. These 
high-risk papillomas overexpress the a6p4 integrin 
and are deficient in transforming growth factor P1 and 
fJ2 peptides, two changes associated with a very high 
proliferation rate in this subset of tumors. The intro­
duction of an oncogenic rasH- gene into epidermal cells 
derived from transgenic mice with a null mutation in 
the TGFp1 gene have an accelerated rate of malignant 
progression when examined in .,ivo. Thus members of 
the TGFp gene family contribute a tumor-suppressor 
function in carcinogenesis. Accelerated malignant 
progression is also found with v-rasH- transduced kera­
tinocytes from skin of mice with a null mutation in the 
p53 gene. The similarities in risk for malignant con­
version by initiated keratinocytes from TGp1 and p53 
null geneotypes suggest that a common, growth-re­
lated pathway may underly the tumor-suppressive 
functions of these proteins in the skin carcinogenesis 
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context of the intact epidermis. In cell culture, initiated keratino­
cytes display an altered response to signals for terminal differentia­
tion, a characteristic that provides a selective growth advantage 
under culture conditions favoring differentiation [2-4]. Exploita­
tion of this difference in vitro has been particularly helpful in isolat­
ing initiated keratinocytes of mouse and human origin [5-8]. 
Exogenous tumor promotion causes the selective clonal expan­
sion of initiated cells to produce multiple benign squamous cell 
papillomas, each representing a clone of thousands of initiated cells. 
Potent exogenous promoters of the phorbol ester class activate, 
protein kinase C (PKC), and this enzyme activity accelerates epi­
dermal terminal differentiation [9-11]. Because initiated cells resist 
the induction of terminal differentiation by activators ofPKC [12], 
the differential response to phorbol esters favors the growth of the 
initiated subpopulation. This process recapitulates in vivo, the clonal 
selection of initiated cells by differentiation inducing agents in ke­
ratinocyte culture [13-15]. Squamous papillomas demonstrate a 
�ign proliferation rate and delayed maturation, properties that are 
analogous to the phenotype of individual initiated cells in vitro 
[16,17]. Because most exogenous promoting agents are not muta­
genic [1], papillomas are diploid [18,19], and a single genetic change 
in normal keratinocytes is sufficient to produce a papilloma pheno­
type [20-22], the mechanism of exogenous promotion is likely to 
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Figure 1. Operational stages in experimental skin carcinogenesis. 
Each stage is defined by the biologic consequences of a specific experimental 
protocol. This scheme serves as a framework for molecular analysis of multi-
stage carcinogenesis. See text and [1] for details. i 
be epigenetic in most cases. In the absence of exposure to exogenous 
promoters, initiated skin rarely develops tumors. Thus, exogenous 
promotion is a rate-limiting early event in carcinogenesis. 
Premalignant progression is most often a spontaneous process, 
independent of exogenous promoters [23,24]. Genetic studies indi­
cate that non-random sequential chromosomal aberrations are asso­
ciated with premalignant progression [19,25-28]. This stage of 
cancer pathogenesis constitutes the major time-dependent compo­
nent of carcinogenesis and must involve repeated episodes of cell 
selection since modal dominance of a specific chromosomal aberra­
tion indicates clonal outgrowth. Thus, at least one function of the 
relevant genetic events occurring during premalignant progression 
must impart a growth advantage on the affected cell. 
Malignant conversion of benign tumors is a relatively rare occur­
rence; less than 5% of papillomas spontaneously convert to cancers 
[23,24]. The risk for malignant conversion is variable among benign 
tumors, and subpopulations of papillomas with a much higher risk 
for malignant conversion have been identified [29 -31]. Because the 
conversion frequency can be significantly increased by exposing 
animals bearing benign tumors to mutagens, the crucial events in 
the conversion process appear to be genetic in nature [23,24]. How­
ever, even mutagen-induced malignant conversion varies in fre­
quency, and the subclass of papillomas at high risk for spontaneous 
conversion is also at higher risk for mutagen-induced conversion 
[30]. Thus, the factors that determine risk for conversion to malig­
nancy must increase susceptibility to spontaneous or induced ge­
netic changes. The identification of these factors would be an im­
portant goal in understanding cancer pathogenesis. 
THE METABOLIC BASIS OF INITIATION INDUCED 
BY A ras ONCOGENE 
The mutational basis for initiation of mouse epidermal carcinogen­
esis was supported by the discovery that the c-rasHa gene was fre­
quently mutated in chemically-induced squamous papillomas, and 
the site of the mutation was determined by the initiating carcinogen 
[32-37]. A causal relationship for a ras mutation and initiation of 
skin carcinogenesis was established when an activated v-rasHa onco­
gene was introduced into normal epidermis or cultured keratino­
cytes and recipient cells developed into squamous papillomas in vivo 
120,38]' Subsequent studies indicated that a significant number of 
human skin cancers also contained mutated c-ras genes [39-44]. 
We have used cultured keratinocytes into which the v-rasHa gene 
was introduced via retroviral transduction to further characterize 
the initiated phenotype and to identify pathways affected by the 
expression of the v-rasHa p21 oncoprotein [45 -47]. 
Primary keratinocytes expressing the v-rasHa oncogene, intro­
duced by a defective retroviral vector, exhibit an altered response to 
signals for terminal differentiation in cell culture and produce squa­
mous papillomas when grafted onto nude mice [20,45-47]. Thus, 
this single gene change can accomplish all the requirements for 
initiation. In cultures of normal keratinocytes, increasing extracel­
lular Ca++ from 0.05 to 0.12 mM induces both mRNA transcripts 
and protein for several differentiation markers, including keratin 1 
(Kl), KI0, loricrin, filaggrin, and keratinocyte transglutarninase 
(TGJ [48,49] (Fig 2). In v-rasHa keratinocytes, Ca++ -mediated ex-
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pression of mRNA for K1 and K10 is blocked, loricrin and fiJaggrin 
expression are enhanced, and TGK is expressed constitutively (Fig 
2). Similar changes in expression of these epidermal markers had 
been documented in normal keratinocytes treated with PKC activa­
tors such as phorbol esters and diacylglycerol (Fig 2) [11,12,47,50]. 
Furthermore, diacylglycerol levels are markedly elevated in v-rasH. 
keratinocytes and in keratinocytes expressing a mutated c-rasHa, 
when compared to normal epidermal cells [51,52]. Diacylglycerol is 
the endogenous activator ofPKC [53,54]. When PKC activity was 
measured in v-rasH. keratinocytes and compared to activity in nor­
mal epidermal cells, PKC activity that is Ca++-dependent was in­
creased whereas PKC activity that is Ca++-independent was de­
creased in the v-rasHa initiated cells (not shown). To examine if the 
PKC pathway could be responsible for the phenotypic alterations in 
v-rasHa keratinocytes, inhibitors of PKC were used to determine 
their influence on the expression of epidermal markers in cells initi­
ated by v-rasHa transduction. Both constitutive and Ca++-induced 
expression ofTGK mRN A in v-rasHa keratinocytes was prevented by 
inactivating PKC with bryostatin or GF 109203X, selective PKC 
inhibitors. Bryostatin treatment also restored the Ca++-induced ex­
pression ofK1 and K10 to v-rasH. cells (not shown). These findings 
support the hypothesis that rasHa-induced alterations in keratino­
cyte differentiation are the result of chronic activation of a Ca++ -de­
pendent isoform of PKC and reduced activity of a Ca++ -indepen­
dent isoform of PKC. Thus, pharmacologic modulation of this 
pathway may provide an approach to reverse the neoplastic pheno­
type. 
Since PKC activation results in terminal differentiation of normal 
keratinocytes [9-11], the chronic activation of PKC measured in 
v-rasHa keratinocytes that did not spontaneously undergo terminal 
differentiation presented a paradox. Neoplastic keratinocyte cell 
lines expressing an activated c-rasH• gene also have elevated diacyl­
glycerol levels [52] , but are resistant to terminal differentiation in­
duced by either Ca++ or phorbol esters. This suggested that qualita-
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Figure 2. Protein kinase C activation and the v-rasH- oncogene block 
expression of mRNA for spinous cell markers and enhance expres­
sion of mRNA for granular cell markers. Mouse keratinocytes were 
cultured in Eagles medium containing 8% fetal bovine serum and a Ca++ 
concentration of 0.05 mM . Some cultures were transduced with the v_rasH. 
oncogene nsing a defective retroviral vector as described previously (20). 
After 8 d in vitro a subset of cultures was switched to medium containing 
0.12 mM Ca2+ for 24 h. In one group of cells the 0.12 mM Ca++ medium 
was supplemented with 125 pM 1-oleoyl-2-acetylglycerol (OAG), a syn­
thetic diacylglycerol that activates PKC [11]. Total RNA was isolated, sepa­
rated on a 1 % agarose gel containing 0.6 M formaldehyde and Northern blot 
analysis performed as described previously (\ \ ,. A.t the timepoint examined 
(24 h), transcription of the later markers, loricrin and filaggrin, is low in 
normal keratinocytes (48). 
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tive changes in PKC isoforms may also contribute to the initiated 
phenotype and could account for differences in Ca++-dependent 
and independent PKC activity in v-rasfh keratinocytes. PKC is a 
family of enzymes, members of which are differentially expressed in 
particular tissues and cell types [55]. Five PKC isozymes are ex­
pressed in keratinocytes (a, �, E, C, ,,) [56]. Of these, PKCa is the 
only Ca++ -dependent isoform. In an analysis of modification of 
these isoforms, we found tyrosine phosphorylation of PKC� in 
v-rasfh keratinocytes [57]. PKC� was also tyrosine phosphorylated 
in neoplastic keratinocytes containing an activated allele of the c­
rasH. gene. The activity of tyrosine phosphorylated PKC� was con­
stitutively low and could not be stimulated significantly by phorbol 
ester treatment, indicating that tyrosine phosphorylation blocks ac­
tivation of PKC� [57]. This interaction between tyrosine kinases 
and PKC permits signaling through specific PKC isozyme in cells 
expressing an oncogenic rasfh gene and may represent a molecular 
block to differentiation in neoplastic keratinocytes. 
CHARACTERISTICS OF TUMORS AT HIGH RISK FOR 
MALIGNANT CONVERSION 
Variations in protocols used for inducing skin tumors yield sub­
groups of papillomas with either low or high risk for progression to 
malignancy [32] . High risk tumors represent a relatively small co­
hort of papillomas. They are selectively induced by limited expo­
sure to strong promoters or by more prolonged exposure to weak 
promoters [32] . Thus, they appear to be more sensitive to exogenous 
tumor promotion. In addition, high risk papillomas erupt early, 
grow larger, and do not regress when promoter exposure is discon­
tinued. Thus, high risk papillomas have unique growth properties. 
We have performed comparative phenotypic analyses of high and 
low risk papillomas to identify differences that may suggest a mo­
lecular basis for the altered biologic potential of this class of benign 
tumors. Several tumor induction protocols were utilized that pref­
erentially produce each papilloma subtype. The tumors were evalu­
ated at the time they first erupted (8 -11 weeks) and sequentially 
during the course of tumor progression. Particular attention was 
concentrated on expression of specific integrins and cytokeratins as 
changes in these markers previously were identified with particular 
stages of skin tumor progression [58,59]. High-risk papillomas 
demonstrated basal and suprabasal expression of the a6p4 integrin, 
loss of keratin 1, and aberrant expression of keratin 13 when they 
first erupted at 8 weeks after promotion started (Fig 3a,b.c). In these 
tumors, a6p4 integrin expression coincided with an expansion of 
the proliferating compartment as indicated by suprabasal bromo­
deoxyuridine labeling [60]. In contrast, a6p4 immunostaining was 
confined to basal cells in low risk tumors, keratin 1 was abundant, 
and keratin 13 was absent or focal in the majority of this group, 
whereas proliferating cells were largely in the basal compartment 
(Fig 3d,e!). By 33 weeks after promotion started, a6p4 suprabasal 
expression continued to distinguish papillomas at higher risk for 
malignant conversion, but keratin 13 was expressed in all groups 
(Fig 4). At this time, high risk papillomas displayed focal expres­
sion of keratin 8 [46,61,62] and y-glutamyltranspeptidase, markers 
also found in chemically-induced carcinomas but not low-risk 
tumors (Fig 4). Keratin 13 was lost in most carcinomas. Keratin 8 
and y-glutamyltranspeptidase were only expressed in a6p4 positive 
cells [60]. These results indicate that expression of a6p4 integrin in 
suprabasal strata serves as an early predictive marker to identify 
benign squamous tumors at high risk for malignant progression and 
that this marker is associated with a higher proliferation rate and 
suprabasal proliferation in high-risk tumors. 
GROWTH FACTORS AND THE RISK FOR 
MALIGNANT CONVERSION 
The transforming growth factor-p's are expressed in the epidermis 
and are growth inhibitors for both normal and initiated mouse kera­
tinocytes in vitro [63]; altered TGF-p expression could influence the 
growth properties of high risk papillomas. Normal epidermis, and 
skin papillomas at low risk for malignant conversion express TGF­
P1 in the basal cell compartment and TGF-fJ2 in the suprabasal 
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Figure 3. Immunohistochemical markers distinguish high risk and 
low risk papillomas. Papillomas were generated on the skin of SEN CAR 
mice by initiation with 10 pg of7,12-dimethylbenz[a]anthracene and pro­
motion with 12-0-tetradecanoylphorbol-13-acetate (TPA, 2 JAg, once 
weekly) to produce papillomas at low risk for malignant progression or 
mezerein (4 JAg, twice weekly) to produce papillomas at high risk for malig­
nant progression [31]. High risk papillomas (a,b,e) were excised at 8 weeks 
when they were first detected clinically and only about 1-2 mm in diame­
ter. Low risk papillomas (d,ef) were excised at 11 weeks, also at first detec­
tion. Frozen sections were processed for immunochemistry using specific 
antibodies for the 0:6 integrin subunit (a,d), keratin 1 (b,e) and keratin 13 
(ef). Reagents and procedures for frozen sectious and immunochemistry 
have been described previously [59]. Each panel represents a 5-p.m frozen 
section through the entire tumor. Bar, 200 JAm. 
strata [17] . In low-risk tumors, 90% of the proliferating cells are 
confined to the basal compartment. In contrast, the majority of high 
risk papillomas are devoid of both TGF-p1 and TGF-fJ2 as soon as 
they arise; these tumors have up to 40% of the proliferating cells in 
the suprabasal layers [17]. Squamous cell carcinomas are also devoid 
of TGF-p [17,64], suggesting that they arise from the TGF-p­
deficient high-risk papillomas. In some high-risk papillomas, 
TGF-p loss can occur first and correlates with basal cell hyperpro­
liferation, whereas TGF-fJ2 loss correlates with suprabasal hyper­
proliferation. In tumors, loss of TGF-p is controlled at the post­
transcriptional level [17,64]. These results show that TGF-p ex­
pression and function are compartmentalized in epidermis and 
epidermal tumors, and that loss ofTGF-p is an early, biologically 
relevant risk factor for malignant progression. 
The importance ofTGF-p loss in progression was demonstrated 
directly using transgenic mice with null mutations introduced into 
the TGF-p110cus [65]. Keratinocyte cultures were established from 
epidermis of newborn mice either homozygous or heterozygous for 
the TGF-p1 null mutation or from wildtype littermates. The v­
rasH. oncogene was introduced by a defective retrovirus into cells of 
each genotype, and recipient cells were grafted onto nude mouse 
hosts. As expected, the v-rasH'-transduced wild type keratinocytes 
produced benign papillomas in grafts. In contrast, the tumors that 
developed from v-rasH'-transduced TGF-p1 null keratinocytes were 
either very dysplastic papillomas or squamous cell carcinomas. 
These results provide strong genetic proof to indicate that the loss of 
TGF-p1 is a critical step in the progression to malignancy in the 
e�idermis. . 
THE P53 TUMOR SUPPRESSOR GENE AND 
MALIGNANT CONVERSION 
The p53 gene is frequently mutated in human squamous cell and 
basal cell carcinomas of the skin [66-69]. This is likely to result 
from the direct mutational action of ultraviolet light since the most 
frequent mutagenic change is a C -+ T transition commonly found 
at C-C dinucleotides [66-69]. The E6 transforming gene of onco­
genic human papilloma viruses targets p53 protein to fonn a rapidly 
degraded complex. This action of E6 is essential for transforming 
activity of this virus for cultured keratinocytes [70-73]. Together 
these results suggest an important role for p53 in epidermal carcino­
genesis. In experimental mouse skin carcinogenesis, p53 mutations 
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Figure 4. Low-risk tumors are phenotypically distinct from carci­
nomas after 33 weeks of tumor promotion. Tumors were induced by 
the low-risk protocol described in the legend to Fig 3. After 33 weeks 
papillomas were excised for immunohistochemical staining of frozen sec­
tions (a,b,c). Simultaneous staining was performed on the few carcinomas 
that also develop from this protocol (d,eJ). The specific antibodies used were 
to recognize (a,d) keratin 13; (b,e) a6 integrin subunit; (en keratin 8. Re­
agents and procedures have been reported previously [60]. Bar, 100 Jlm. 
are extremely rare in papillomas, but mutations are detected in car­
cinomas [74-77]. This suggests that loss of p53 function may be 
relevant to malignant conversion [78]. To test this question, kerati­
nocytes from skin of newborn p53 null transgenic mice [79] were 
cultured and transduced with the v-rasH> gene in experiments simi­
lar to those performed on TGF-fJ1 null mice. In all groups large 
tumors were apparent two weeks after grafting. Mice grafted with 
p53(+j+) keratinocytes developed papillomas (eight of eight), 
whereas all mice grafted with p53(-j-) keratinocytes developed 
squamous cell carcinomas (eight of eight). p53(+ j-) cells produced 
rapidly growing papillomas; 10 of 19 of these papillomas progressed 
to carcinomas within five weeks (Fig 5). Thus, loss of the p53 
protein in combination with a mutant rasH> gene is associated with 
the malignant conversion stage of epidermal carcinogenesis . 
CONCLUSIONS 
The use of molecular approaches to analyze established biologic 
concepts has provided insights into functional changes in cell physi­
ology during carcinogenesis. We now recognize that the initiated 
phenotype results from intrinsic changes in intracellular signaling 
pathways, particularly those related to terminal differentiation. 
When activation of the c-rasH> gene is responsible for initiation of 
keratinocyte neoplasia, a critical target is the PKC pathway. The 
five PKC isoforms in keratinocytes contribute to specific compo­
nents of the differentiation response. Presently, the analysis suggests 
that chronic activation of PKCa through increased cellular diacyl­
glycerol and functional inhibition ofPKCa due to phosphorylation 
on tyrosine residue(s) contribute to the altered differentiation re­
sponse characteristic of initiated epidennal cells. 
Extrinsic tumor promotion and premalignant progression are as­
sociated with changes in extrinsic signaling pathways. The control 
of proliferation of neorlastic epidermal cells seems central to these 
stages. Selective clona expansion of the neoplastic population is a 
requirement. The accumulation of genetic and chromosomal 
changes associated with frogression may be a consequence of al­
tered proliferation contro . We now know that loss of expression or 
localization of the TGF-fJ class of growth factors is a common 
pathway through which premalignant progression proceeds in skin 
carcinogenesis. Loss of response by neoplastic cells to negative 
growth factors such as TGFfJ mar be an alternative pathway to 
achieve the same endpoint [80-84. Loss ofTGF-fJ responsiveness 
has been associated with mutation and functional inactivation in 
p53 [85 ,86] and could account for the accelerated skin tumor pro­
gression observed for both p53 and TGF-fJ null mice transduced 
with the v-rasH> gene. 
The molecular ,basis for malignant conversion is still under inves-
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Figure S. Tumors induced on nude mice from grafts of keratino­
cytes expressing the v-rasHo oncogene. Skin keratinocytes were cultured 
from p53 null transgenic mice (e) or their wildtype (a) or heterozygous (b) 
littermates. In culture, cells of each genotype were transduced with the 
v-rasH> oncogene by a defective retroviral vector and removed from culture 
after 3 d for skin grafting as described [20]. Within 3-5 weeks, tumors 
developed on recipient mice that had either the benign (a,b) or malignant (e) 
phenotype. See text for quantitative evaluation. Bar, 1 cm. 
tigation. In previous studies we have shown that a v-fos oncogene 
can cause malignant conversion of benign keratinocytes expressing 
a ras oncogene [87,88]. Because thefos gene product is a transcrip­
tion factor known to regulate the expression of a number of genes 
that contain AP-1 consensus sequences [89,90], the converting ac­
tion of v-fos is likely to result from altered expression of normal 
cellular genes. We are currently attempting to identify those cellu­
lar genes that may be contributing to the malignant phenotype of 
keratinocytes. 
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